Related Experiment Video
Updated: Jul 19, 2026
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
[Prognostic value of early treatment response in children with acute myeloid leukemia]
Li-Jun Tie1, Long-jun Gu, De-lian Song
1Department of Hematology/Oncology, Affiliated Shanghai Children's Medical Center of Medical College of Shanghai Jiaotong University, Shanghai 200127, China.
Insights
Early treatment response in pediatric acute myeloid leukemia (AML) is a significant prognostic indicator. Measuring blast cells 48 hours after induction treatment can predict complete remission, guiding therapy for better outcomes.
Area of Science:
- Pediatric Hematology Oncology
- Clinical Trial Research
- Leukemia Biology
Context:
- Acute myeloid leukemia (AML) in children presents unique challenges in treatment and prognosis.
- Early assessment of treatment efficacy is crucial for optimizing therapeutic strategies.
- Understanding prognostic factors aids in stratifying risk and personalizing care for pediatric AML patients.
Purpose:
- To evaluate the prognostic significance of early treatment response in pediatric acute myeloid leukemia (AML).
- To determine if the number of bone marrow blast cells 48 hours after induction treatment predicts complete remission.
- To identify early treatment response as a predictor of event-free survival (EFS) in children with AML.
Summary:
- A study of 61 children with AML found that blast cell counts 48 hours post-induction treatment were highly correlated with complete remission rates.
- Patients achieving complete remission after the first induction course had significantly higher 5-year event-free survival (EFS) compared to those who did not.
- Early blast cell reduction (<0.15) was associated with improved EFS (49% +/- 11%) versus higher counts (18% +/- 15%), highlighting its prognostic value.
Impact:
- Early treatment response, specifically blast cell count post-induction, is a powerful predictor of complete remission in pediatric AML.
- This finding can inform treatment decisions and risk stratification, potentially improving outcomes for children with AML.
- The study underscores the importance of monitoring early treatment response for timely therapeutic adjustments in pediatric acute myeloid leukemia management.
Objective:
To assess the prognostic value of early treatment response in children with acute myeloid leukemia (AML).
Methods:
Sixty-one children with AML, 37 male and 24 female, aged 96 months (6 - 154 months), underwent treatment according to the protocol AML-XH-99 with a total treatment course of 15 months and were followed up for 12 months (1 - 74 months). Bone marrow smear was made 48 hours after the end of the first course of induction treatment. Then the children were divided into 2 groups according to the number of bone marrow blast cells: group with the number of blast cells > or = 0.15 and group with the number of blast cells < 0.15. Second bone marrow smear was made when complete remission was achieved after the end of the treatment course. Then the children were divided into 2 groups according to the number of bone marrow blast cells: group with the number of blast cells of 0.00 and group with the number of blast cells between 0.00 and 0.05. The probability of event-free survival (EFS) was estimated by Kaplan-Meier analysis. Log-rank test was used to compare the 5-year EFS (pEFS) of different groups. The differences in the biological features were compared by Chi-square analysis or Fisher exact test.
Results:
The pEFS of the group with the number of blast cells > or = 0.15 was 18% +/- 15%, significantly shorter than that of the group with the number of blast cells < 0.15 (49% +/- 11%, P = 0.079). The 3 patients without morphologically identifiable blast all survived 5 years after complete remission had been achieved, and the pEFS of the 39 patients with the number of blast cells between 0.00 and 0.05 was 53% +/- 10%. The pEFS of the patients among which complete remission was achieved after the first course of treatment (n = 39) was 54% +/- 10%, significantly higher than that of the patients without complete remission after the first course of treatment (10% +/- 9%, P = 0.0002). Multiple factor analysis showed that achievement of complete remission after the first course of treatment and existence of central nervous system leukemia were both independent prognostic factors with the hazard ratios of 4.007 and 7.050 respectively and the 95% confidential intervals of 1.019 to 6.163 and 0.018 to 0.547 respectively (P = 0.045 and P = 0.008). The number of blasts 48 hours after the end of the first course of induction treatment was highly correlated with the rate of complete remission after the first treatment course (P = 0.000 028 8).
Conclusion:
With important prognostic significance, early treatment response, such as the number of blasts 48 hours after the end of the first course of induction treatment can predict whether complete remission can be achieved.
